Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Outpatient HiDAC for Older AML Patients
NCT02101983Completed
- Sponsor
- University of Rochester
- Start
- May 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by University of Rochester. Primary endpoint: Number of Participants With Grades 3 to 5 Non-hematologic Toxicity at 3 months. Started May 2011; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02101983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101983.